Funding, launches and regulatory moves across the neurotech startup map.
Subscribed. Check your inbox to confirm.
MintNeuro
news and updates
7 Oct 2026: MintNeuro raised $5M led by Odyssey Ventures, with 33East, JSK Investments and Alumni Ventures, plus returning investors Empirical Ventures and Jumpspace Ventures. Its MN100 sensing chip and MN200 stimulation chip are at working-silicon stage. The funding goes toward a product launch, shipping pre-release silicon to partners, and a US presence. Read our coverage.
May 2026: MintNeuro signed a multi-year agreement to supply chips for Motif Neurotech’s implant for treatment-resistant depression. The deal came days after Motif received FDA approval to start a clinical study. MintNeuro also partners with Amber Therapeutics. Read our coverage.
•
Neurofounders Insights
$ Funding -
Non-dilutive
MODALITY
Intracortical
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Multi-indication
TARGET USER
Mixed
REGULATORY STAGE
Research only
MintNeuro is best understood as deep-tech semiconductor infrastructure for neurotechnology, focusing on power-efficient chips that could shrink and scale implants. This is a valuable but upstream position in the stack, making it more comparable to component suppliers than device companies.
MintNeuro raised $5M, led by Odyssey Ventures, to scale its low-power neural chips for sensing, processing, and stimulation. The London company already supplies Motif Neurotech under a multi-year agreement and plans to expand in the US.